Avoid These Recently Downgraded Stocks

The latest POWR Ratings are in. Each day, our POWR Ratings system evaluates stocks on numerous factors. This results in stock upgrades and downgrades. All in all, the POWR Ratings are calculated on 6,000+ stocks and ETFs. Thankfully, the latest POWR Ratings updates reveal more upgrades than downgrades…

But below, we provide a look at four of the latest POWR Ratings downgrades so you can avoid them: Luminar Technologies (LAZR – Get Rating), Seres Therapeutics (MCRB – Get Rating), Sabre Corporation (SABR – Get Rating), and Murphy Oil (MUR – Get Rating).

Luminar Technologies (LAZR – Get Rating)

LAZR specializes in sensors and software for autonomous automobiles. Previously known as Gores Metropoulos, LAZR is based in Florida. Though LAZR received plenty of attention for a December tweet that noted its sensors were employed on a Tesla (TSLA) vehicle, Tesla’s founder, Elon Musk, insisted that his company’s cars do not use such sensors. 

Furthermore, this might have been a trial run, so there is no tangible proof that Tesla and LAZR are official partners. In terms of the POWR Ratings, LAZR has “D” grades in the Buy & Hold Grade, Peer Grade, and Trade Grade components. IT is also ranked 58th out of 67 publicly traded companies in the Auto Parts industry.

The bottom line is LAZR will only meet expectations if autonomous driving fulfills its potential sooner. LAZR has not proven it has the manufacturing capabilities necessary to hit its sales estimate of $837 million by 2025. LAZR’s revenue for the current year is likely to come in at a mere $15 million.

Seres Therapeutics (MCRB – Get Rating)

MCRB provides a platform for microbiome therapeutics. The company’s primary focus is developing Ecobiotic microbiome therapeutics for the treatment of dysbiosis within the colonic microbiome.

The POWR Ratings reveal MCRB has “D” grades in the Peer Grade, Trade Grade, and Buy & Hold Grade components. MCRB is ranked 244 out of 483 stocks in the Biotech industry. MCRB has a three-month return of -22.53%.

There is still some question as to whether the gut microbiome will alter the course of medicine, meaning investing in…

Continue reading at STOCKNEWS.com